Liege

• Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant a … Ended
  2023-503945-78-00 3 2023-06-13 Narcolepsy with cataplexy
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended
  2024-512649-18-00 5 2023-06-05 Thyroid Eye Disease
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn … Ended
  2023-508777-91-00 10 2023-05-16 Moderately to Severely Active Crohn's Disease
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended
  2022-501586-50-00 5 2023-05-15 Atopic Dermatitis
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytom … Ended
  2022-501423-25-00 7 2023-05-05 Surgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular
• A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lun … Ended
  2023-505540-19-00 10 2023-04-24 Pulmonary Hypertension Associated with Interstitial Lung Disease
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Primary carE PPi dEprescRibing (PEPPER) trial Ended
  2022-502375-37-00 6 2023-04-16 heartburn
• A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants Ended
  2022-502926-42-00 1 2023-03-30 Respiratory syncytial virus infection
• A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission … Ended
  2022-502241-99-00 1 2023-03-20 Crohn's Disease
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended
  2024-511089-36-00 4 2023-03-17 Crohn’s disease
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended
  2022-501183-17-00 7 2023-02-23 Non-Small Cell Lung Cancer
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 4 2023-02-14 Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or F
• Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma Ended
  2024-511254-51-00 1 2023-02-09 Glaucoma
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis Ended
  2024-512964-73-00 4 2023-01-18 Alport Syndrome (AS) and Primary Steroid-Resistent Focal Segmental Glo
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri

Showing 553–576 of 639 trials